Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of SCC244 (Gumarontinib) in Advanced Solid Tumors
NCT03466268Phase 1Completed
- Sponsor
- Haihe
- Start
- Sep 2017
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glumetinib in non-small cell lung cancer (NSCLC), gastric cancer (GC) and hepatocellular carcinoma (HCC), sponsored by Haihe. Primary endpoints: Dose Limiting Toxicity at 35 days, Maximum Tolerated Dose at 35 days and 2 more. Started Sep 2017; status: completed.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03466268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466268.